Addus HomeCare Corporation
ADUS · NASDAQ
Company research
Addus HomeCare Corporation (NASDAQ: ADUS) is a Frisco, Texas-based provider of in-home personal care, hospice, and home health services, founded in 1979 and serving approximately 62,000 consumers across 260+ locations in 23 states. The company primarily supports elderly, chronically ill, and disabled individuals at risk of hospitalization or institutionalization, with its Personal Care segment — focused on non-medical assistance with daily living activities — representing approximately 76.5% of 2025 net revenues. Addus generates revenue through federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private-pay individuals, with a heavy concentration in Medicaid-funded Personal Care Services. Fueled by an aggressive acquisition strategy — including the landmark $350 million purchase of Gentiva's personal care operations — and a growing elderly demographic, the company reported approximately $1.42 billion in fiscal year 2025 revenue, establishing itself as a dominant, financially disciplined player in the fragmented U.S. home care market.
Research reports
Beanvest presents Addus as a scaled Medicaid-focused home-care platform that compounds predictable free cash flow, supported by modest net leverage, strong balance sheet liquidity, and disciplined acquisitions, while stressing that regulatory changes (such as the CMS Access Rule) and reimbursement and labor dynamics are the main constraints on long‑term margin expansion and a key source of execution risk.
StockStory · March 29, 2026Addus HomeCare (ADUS) Research Report: Q4 CY2025 UpdateStockStory’s Q4 CY2025 update highlights excellent year‑over‑year revenue and EPS growth, improving operating margins, and solid cash generation but ultimately assigns an “Underperform” view, arguing that ADUS’s subscale revenue base, expected deceleration in forward growth, and only middling overall business quality make the stock a relatively weak opportunity versus better healthcare names despite a seemingly attractive valuation.
Macroaxis · March 11, 2026Addus HomeCare Stock Analysis - 2026Macroaxis characterizes ADUS as undervalued, noting a real (intrinsic) value estimate and Wall Street target price well above the current share price, supported by improved profitability metrics, solid profit and operating margins, and a strong analyst consensus “Strong Buy” rating, while warning that rising debt-to-equity and debt ratio trends increase the stock’s financial risk sensitivity and make ongoing balance-sheet discipline important.
Investing.com · September 2, 2025Addus HomeCare's SWOT analysis: stock poised for growth amid challengesInvesting.com’s SWOT analysis emphasizes robust Q2 2025 revenue and EBITDA growth, a healthy gross margin, conservative leverage, and successful acquisitions such as Gentiva’s Personal Care business as drivers of future expansion and analyst price targets implying material upside, but also underscores risks from Medicaid policy uncertainty, underperformance in the Home Health segment, and labor and regulatory pressures that could affect growth and valuation multiples.